Huayu Pharmaceutical: Carbasulfate Sodium Injection Obtains Drug Registration Certificate

Huiyu Pharmaceuticals announced that its wholly-owned subsidiary, Sichuan Huiyu Haiyue Medical Technology Co., Ltd., recently received the "Drug Registration Certificate" for the approved sodium carbidopa injection from the National Medical Products Administration. Sodium carbidopa injection can reduce the permeability of capillaries, promote the retraction of capillary rupture ends, increase the resistance of capillaries to damage, shorten bleeding time, without affecting the blood clotting and fibrinolytic system, and has hemostatic effect. It is suitable for bleeding diseases of the urinary system, upper digestive tract, respiratory tract, and obstetrics and gynecology. The sales of sodium carbidopa injection in China's urban public hospitals terminal in 2024 was 3.39 million RMB. The company has already started the pre-launch sales preparation work for the product.